News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novartis Pharma AG (NVS) In UK Biotech Deal Worth Up To $375 Milllon


10/19/2005 5:13:16 PM

LONDON, April 13 (Reuters) - Swiss drugmaker Novartis AG (NOVN.VX: Quote, Profile, Research) unveiled one of the biggest-ever deals in the European biotech sector on Wednesday, taking on an experimental treatment for smoker's lung from two British firms for up to $375 million. Vectura Plc (VEC.L: Quote, Profile, Research) and privately owned Arakis Ltd said Novartis had agreed to develop and commercialise their AD 237 treatment for chronic obstructive pulmonary disease (COPD), which is primarily caused by smoking.

Read at Reuters
Read at Employment Digest
Read at Dow Jones
Read at Yahoo Finance

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES